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ABSTRACT
The current paradigm in data science is based on the belief that given sufficient amounts of data,
classifiers are likely to uncover the distinction between true and false hypotheses. In particular, the
abundance of genomic data creates opportunities for discovering disease risk associations and help in
screening and treatment. However, working with large amounts of data is statistically beneficial only if
the data is statistically unbiased. Here we demonstrate that amplification methods of DNA samples in
TCGA have a substantial effect on short tandem repeat (STR) information. In particular, we design a
classifier that uses the STR information and can distinguish between samples that have an analyte code
D and an analyte code W. This artificial bias might be detrimental to data driven approaches, and might
undermine the conclusions based on past and future genome wide studies.
Introduction
Genomic studies of complex diseases, commonly referred to as Genome Wide Association Studies
(GWAS)6, flooded the literature soon after the first human genome was sequenced in the early 2000’s8.
These studies aimed to map thousands of small risk variants that collectively affected the occurrence of
the complex disease in question. The variants are detected by comparing the DNA of healthy individuals
against sick individuals. As each complex disease was speculated to be caused by a large number of
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small risk variants, massive amount of genomic data was needed . This became the primary incentive for
projects that collected massive amounts of genomic data, such as the 1000Genome Project1, The Cancer
Genome Atlas (TCGA)21, and UK Biobank17, to name a few.
In addition, recent computational advances in machine learning (ML) tools, such as decision trees and
neural networks, have ignited a data driven learning approach to tackle the complex associations between
variants and their connection to disease risk. The DNA samples used in these studies undergo different
amplification techniques and are derived from many different sources. These differences potentially
contribute distinct noise patterns, specific to a given source or technique4, thus leading to biased data that
could drastically alter the outputs of sensitive ML methods. We demonstrate the existence of such bias in
TCGA and the vulnerability of ML methods to this bias.
Results
To examine this bias, we study the effect of amplification techniques on whole exome sequencing (WXS)
data on TCGA. This data comprises more than 10,000 exomes of both tumor and normal type (blood-
derived or primary tissue) for 33 different cancers, which have been obtained from different sources and
have undergone different amplification techniques. In particular, we compare WXS BAM files labeled
with the analyte code “D” and files with the analyte code “W”. Samples with “W” code have undergone
whole genome amplification (WGA) using Repli-G (Qiagen) technology that uses Multiple Displacement
Amplification (MDA).
By merely using the copy number and number of point mutations in short tandem repeat regions
of normal DNA, we are able to distinguish “D” and “W” category files of the same cancer with high
accuracy (Experiment 1: see Figure 1). We then show that this signal contributes to misclassification
when classifying DNA by cancer type (Experiment 2: see Figure 2). We describe the details of these
experiments below.
In Experiment 1, we consider the normal DNA of 414 patients with Glioblastoma Multiforme (TCGA-
GBM). Of the 414 patients in TCGA-GBM, 164 patients had BAM files with analyte code “W” and the
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Figure 1. An illustration of experiment 1. Here, the placement of bars represent the labeling of the classes. Throughout our
diagrams we color “D” type files red and “W” type files blue. The first column shows the data that our classifier was trained on.
The second column shows where a perfect classifier would put the data, and the third column shows how our classifier labeled
that data. Here we see that, within the cancer class of GBM, we are able to train a fairly accurate classifier for “D” and “W”
files.
rest (250) had analyte code “D”. We train pairwise classifiers using gradient boosting10, 11 (xgboost) to
distinguish the “D” and “W” file types. At test time, 71% of the “D” files in the test set were correctly
classified as “D” and 86% of the “W” files were correctly classified as “W”.
Strong differences, that contribute to this noise signature, are present in specific locations of the
genome. Figure 3 shows the distribution of copy numbers at two different locations in “D” and “W” files
in the normal DNA of TCGA-GBM patients. These differences, alongside point mutations, are present at
many other locations and constitute the data amplification bias which is picked up by the xgboost classifier.
In Experiment 2, we investigate the effect of this amplification bias on cancer prediction. For this
purpose, we took 414 patients of TCGA-GBM (164 of “W” file type and 250 of “D” file type), and
493 patients from TCGA-PRAD, all with “D” file types. We build gradient boosting-based classifiers to
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Experiment 2
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Figure 2. An illustration of experiment 2. Again, the placement of bars represent the labeling of the classes, which this time
is separated by cancer type (GBM vs PRAD). We also continue our convention of coloring the hidden variable “D” type files
red and “W” type files blue. Here, a classifier trained on cancers which differ in their file type appears to be successful in the
first two test sets i.e., GBM “W” files and PRAD “D” files. The testing results for the third test set GBM “D” files, however,
shows that the classification of GBM “D” files is very similar to that of PRAD “D” files. Hence, our machine learning
algorithm has mistaken the D/W signal (blue vs red) for the cancer-type.
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Figure 3. Left: The distribution of copy number at chr3 : 103,964,964−103,965,016. It can be seen that for “W” files the
distribution is concentrated at 24, however for D files the distribution is more spread out. Right: The distribution of copy
number at chr2 : 206,351,442−206,351,488. It can be seen that for most D files, the copy number is 0 showing the absence
of the region, but the distribution of copy number for more than 60 W files is concentrated at 5.
distinguish between normal DNA of the GBM and PRAD cancer patients. For training, we used equal
numbers of GBM type “W” and PRAD type “D” files.
As shown in Figure 2, GBM type “W” files comprise the test set and 98% are classified correctly as
GBM files. When testing on PRAD type “D” files, the majority are also correctly classified as PRAD
files. However, in the last part of the experiment, only 34% of TCGA-GBM type “D” files are correctly
classified as TCGA-GBM, while the majority are incorrectly classified as TCGA-PRAD.
The results of experiment 2 (Fig. 2) show that files are classified as the correct cancer type if they
match the file type of that cancer used in training. However, if the file type is that of the opposite cancer,
they are misclassified, indicating that the amplification bias is stronger than any potential cancer signal. In
fact, we get nearly identical classification results whether we use PRAD type “D” or GBM type “D” test
files, implying that the cancer signal either does not exist or has been severely obscured. With regard to
the question of cancer signal, we have separately analyzed “D” and “W” samples from TCGA in7. In light
of these results, we discuss the repercussions of not considering amplification technique as a confounding
factor in genomic studies.
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Discussion
As artificial intelligence is increasingly relied upon to substitute human reasoning, data bias is an acute
concern. In particular, genomic data is highly susceptible to the source and technology by which it was
generated, and hence may lead to false associations. Figure 1 establishes that there is a sufficient statistical
difference between “D” and “W” file types for the xgboost classifier to identify the amplification bias
present in the training set and distinguish file types. Figure 2 shows the effect this amplification bias has
on the results of experiment 2 which was conducted to find cancer associations. By observing the test
accuracies of 98% and 66% respectively, when testing was only done on GBM “W” file types or PRAD
“D” file types, one might conclude that STR regions in normal DNA of GBM and PRAD patients have
information about the 2 cancer types. However, when testing was done on GBM patients with “D” file
types, we see contradictory results showing a stronger association of TCGA-GBM patients in the test set
with TCGA-PRAD patients in the training set.
This contradictory result is observed due to the amplification bias. Since the training was done on
TCGA-GBM patients with “W” file types and TCGA-PRAD patients with “D” file types, the hidden
“D” vs. “W” signal in the training data overpowers the “GBM vs. PRAD” signal giving misleading
classification accuracies for all test sets considered in experiment 2.
To account for these findings, prior to using any data-driven tool for finding phenotypical associations,
a pre-check must be conducted in order to detect hidden variables, or “noise”, that might subside the true
signal of interest. In our experiments, this hidden variable turned out to be the “D” and “W” file types.
One potential approach to discover these hidden variables is unsupervised learning, where clustering
techniques are used to find unknown associations in the data. Further approaches developed in fairness in
machine learning literature can also be availed2.
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Methods
The classifiers were built using gradient boosting (xgboost) algorithm in the above experiments. 4-fold
cross validation was done before building the final classifiers to identify the parameters. Short tandem
repeats (pattern length ≤ 10) were extracted out of the WXS DNA and the number of copies (d) and
the number of point mutations (m) in each of those tandem repeat regions are used as features (see
Figure 4). Hence, for each tandem repeat region i in a genome, we compute mi and di. If there are N
tandem repeat regions in a DNA, the vector of [(mi,di)]Ni=1 is called the mutation profile. Hence, each
individual’s DNA is represented by this mutation profile, which serves as the input for building the gradient
boosting based classifier. Samtools9 was used to process the BAM files. The repeat regions from the
genome were extracted using Benson Tandem Repeat finder algorithm3 and the mi and di values were
estimated using the single block duplication history algorithm in Tang et al.18. Further details on the
data availability and the Methods details are provided in7. The code for the pipeline used is available at
http://paradise.caltech.edu/~sidjain/Codes.tar.gz.
Figure 4. Pipeline to build a classifier for a given set of classes.
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